First report of serotype 23B
*Streptococcus pneumoniae* isolated from an adult patient with invasive infection in Japan

A. Takamatsu, M. Kawaguchiya, B. Chang, M. Ito, Y. Hirano, S. Katsuta, S. Matsuzaka, Y. Serizawa and N. Kobayashi
1) Department of General Internal Medicine and Infectious Diseases, Teine Keijinkai Hospital, 2) Department of Hygiene, Sapporo Medical University School of Medicine, Sapporo, 3) Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo and 4) BML Clinical Laboratory, Teine Keijinkai Hospital, Sapporo, Japan

**Abstract**

Serotype 23B *Streptococcus pneumoniae* was isolated from a 67-year-old Japanese patient with meningitis. This isolate was susceptible to penicillin G, while genotyped as gPISP with a mutation in a penicillin-binding motif in PBP2b. The 23B isolate was assigned to ST11996 that is related to CC439, a dominant group among serotype 23B.

© 2017 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

**Keywords**: Invasive infection, Japan, serotype 23B, *Streptococcus pneumoniae*

**Original Submission**: 1 November 2016; **Revised Submission**: 3 February 2017; **Accepted**: 28 February 2017

**Article published online**: 9 March 2017

**Corresponding author**: M. Kawaguchiya, Department of Hygiene, Sapporo Medical University School of Medicine, S-1 W-17, Chuo-ku, Sapporo 060-8556, Japan.

**E-mail**: kawaguchiya@sapmed.ac.jp

*S. pneumoniae* is a major cause of invasive infections, particularly in young children and the elderly worldwide. In Japan, a 13-valent pneumococcal conjugate vaccine (PCV13) has been used for routine immunization of children since 2013, and for adults on a voluntary basis since 2014, leading to a rapid reduction in invasive pneumococcal diseases (IPD) [1]. Since then, an increase of *S. pneumoniae* with non-vaccine serotypes has been noted for IPD as well as non-IPD [2–5]. A non-vaccine type, 23B, has not yet been reported in Japan, although its increase was observed in Europe and the USA in the PCV13 era [6–9].

A fully ambulatory 67-year-old Japanese man with a past history of chronic kidney disease was admitted to our hospital in June 2016 for shaking chills and dysarthria without fever. He had no history of pneumococcal vaccination or recent overseas travel. On physical examination, he was lethargic with neck stiffness. Laboratory tests showed leucocytosis (18570/μL; normal range: 3500–9700/μL), elevated creatine level (6.69 mg/dL; normal range: 0.65–1.09 mg/dL), and elevated C-reactive protein level (47.59 mg/dL; normal range <0.30 mg/dL). Computed tomography (CT) revealed splenic hypoplasia without cerebral herniation (Fig. 1a). Cerebrospinal fluid analysis showed pleocytosis (cell

![FIG. 1. Enhanced CT scan of the patient’s abdomen showing splenic hypoplasia (a). T2-weighted sagittal MRI scan of the patient showing increased signal intensity at the L5–S1 level (b).](image-url)
count: 354/\text{mm}^3\), hypoglycorrhachia (0 mg/dL; plasma glucose level: 92 mg/dL), elevated protein (262 mg/dL; normal range: 10–40 mg/dL), and presence of Gram-positive diplococci and pneumococcal antigen. He was diagnosed with pneumococcal meningitis. Ceftriaxone (2 g twice daily) and vancomycin (1 g twice daily) with dexamethasone (10 mg four times daily) were administered intravenously. *Streptococcus pneumoniae* (MIC of penicillin G \( \leq 0.03 \text{ mg/L} \)) was isolated from blood and cerebrospinal fluid, and antibiotics were changed to intravenous ampicillin (3 g three times daily) on the 5th hospital day. Blood cultures turned negative from the 8th hospital day forward. On the 13th hospital day, he complained of low back pain. A T2-weighted MRI revealed increased signal intensity at the L5–S1 level, indicating osteomyelitis (Fig. 1b). Ampicillin was changed to ceftriaxone and oral rifampicin (600 mg/day). The patient was subsequently treated with intravenous antibiotics for 6 weeks, and discharged with oral amoxicillin (2 g/day) for another 2 weeks.

The *S. pneumoniae* isolate designated AT0814 was serotyped as 23B by Quellung reaction, and also by sequential multiplex PCR [10]. The wzx gene sequence of this isolate was identical to that of the 23B strain 1039/41, whereas it showed 81% identity to those of 23F and 23A strains. The isolate AT0814 was found to be susceptible to all the 18 antimicrobials as determined by the broth microdilution test. However, the PBP genotype was determined to be gPISP (pbp2b). Sequence analysis of *pBP* (GenBank Accession Nos KX698435–KX698437) revealed that PBP2b had an amino acid substitution in the penicillin-binding motif (442SSNT445). PCR revealed increased signal intensity at the L5–S1 level, indicating osteomyelitis (Fig. 1b). Ampicillin was changed to ceftriaxone and oral rifampicin (600 mg/day). The patient was subsequently treated with intravenous antibiotics for 6 weeks, and discharged with oral amoxicillin (2 g/day) for another 2 weeks.

The *S. pneumoniae* isolate designated AT0814 was serotyped as 23B by Quellung reaction, and also by sequential multiplex PCR [10]. The wzx gene sequence of this isolate was identical to that of the 23B strain 1039/41, whereas it showed 81% identity to those of 23F and 23A strains. The isolate AT0814 was found to be susceptible to all the 18 antimicrobials as determined by the broth microdilution test. However, the PBP genotype was determined to be gPISP (pbp2b). Sequence analysis of *pBP* (GenBank Accession Nos KX698435–KX698437) revealed that PBP2b had an amino acid substitution in the penicillin-binding motif (442SSNT445). PCR revealed increased signal intensity at the L5–S1 level, indicating osteomyelitis (Fig. 1b). Ampicillin was changed to ceftriaxone and oral rifampicin (600 mg/day). The patient was subsequently treated with intravenous antibiotics for 6 weeks, and discharged with oral amoxicillin (2 g/day) for another 2 weeks.

This is the first report of *S. pneumoniae* serotype 23B in Japan. The isolate AT0814 was derived from IPD, and demonstrated a gPISP genotype and various virulence factors. Special attention must be paid to the prevalence and antimicrobial susceptibility of this serotype in the PCV era.

**Conflicts of Interest**

None to declare.

**Acknowledgement**

This study was supported by a Grant-in-Aid for Scientific Research (KAKENHI) (16K09101) from the Japan Society for Promotion of Science (JSPS).

**References**

[1] Suga S, Chang B, Asada K, Akeda H, Nishi J, Okada K, et al. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: effects of the seven-valent pneumococcal conjugate vaccine. Vaccine 2015;33:6054–60.

[2] Chiba N, Morozumi M, Shoju M, Wajima T, Iwata S, Ubukata K, et al. Changes in capsule and drug resistance of pneumococci after introduction of PCV7, Japan, 2010–2013. Emerg Infect Dis 2014;20:1132–9.

[3] Nakano S, Fujisawa T, Ito Y, Chang B, Suga S, Noguchi T, et al. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive *Streptococcus pneumoniae* isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012–2014. Vaccine 2016;34:67–76.

[4] Ubukata K, Chiba N, Hanada S, Morozumi M, Wajima T, Shoju M, et al. Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010–2013. Emerg Infect Dis 2015;20:1956–65.

[5] Kawaguchiya M, Urushibara N, Aung MS, Morimoto S, Ito M, Kudo K, et al. Emerging non-PCV13 serotypes of noninvasive *Streptococcus pneumoniae* with macrolide resistance genes in northern Japan. New Microbes New Infect 2015;9:66–72.

[6] Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011. Emerg Infect Dis 2013;19:1074–83.

[7] Steens A, Bergsaker MA, Asberg E, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013;31:6222–8.

[8] van der Linden M, Perniciaro S, Imoh M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis 2015;15:207.

[9] Slotved HC, Dalby T, Hoffmann S. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark. Vaccine 2016;34:769–74.

[10] Carvalho MDG, Pimenta FC, Jackson D, Roundtree A, Ahmad Y, Millar EV, et al. Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotype. J Clin Microbiol 2010;48:1611–8.